4815-37-6

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 2-AMINO-5-METHYL-4-PHENYLTHIOPHENE-3-CARBOXYLATE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of novel drug molecules. Its unique structural features allow for the creation of compounds with potential therapeutic applications, addressing various medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, ETHYL 2-AMINO-5-METHYL-4-PHENYLTHIOPHENE-3-CARBOXYLATE is utilized as a precursor in the production of agrochemicals. Its incorporation into these products can enhance their effectiveness in pest control and crop protection, contributing to improved agricultural yields and sustainability.
Used in Organic Synthesis:
ETHYL 2-AMINO-5-METHYL-4-PHENYLTHIOPHENE-3-CARBOXYLATE is employed as a versatile building block in organic synthesis, allowing for the creation of a wide range of organic compounds. Its unique functional groups enable chemists to modify and extend its structure, leading to the development of new molecules with diverse applications in research and industry.
Used in Research and Development:
ETHYL 2-AMINO-5-METHYL-4-PHENYLTHIOPHENE-3-CARBOXYLATE is also used in research and development settings, where its properties are explored for potential applications in various fields. The exploration of its reactivity, stability, and interaction with other molecules can lead to the discovery of new chemical processes and the creation of innovative materials.

InChI:InChI=1/C14H15NO2S/c1-3-17-14(16)12-11(9(2)18-13(12)15)10-7-5-4-6-8-10/h4-8H,3,15H2,1-2H3

Upstream product

• 13434-46-3 ethyl 2-cyano-3-phenylpent-2-enoate 
• 105-56-6 ethyl 2-cyanoacetate 
• 14442-48-9 (E/Z)-ethyl 2-cyano-3-phenylpent-2-enoate 
• 93-55-0 1-phenyl-propan-1-one 

Downstream Products

• 109164-43-4 2-(3-Carboxy-propionylamino)-5-methyl-4-phenyl-thiophene-3-carboxylic acid ethyl ester 
• 151258-65-0 2-(1-pyrrolyl)-4-phenyl-5-methylthiophen-3-carboxylic acid 
• 151258-68-3 N,N-dimethyl 2-(1-pyrrolyl)-4-phenyl-5-methylthiophen-3-carboxamide 
• 1190768-28-5 C₂₃H₂₃NO₄S 
• 1190765-88-8 4-hydroxy-5-(2-hydroxyphenyl)-3-phenyl-2-methyl-6,7-dihydro-thieno[2,3-b]pyridin-6-one 
• 1190767-71-5 4-hydroxy-5-(2-methoxyphenyl)-2-methyl-3-phenyl-6,7-dihydro-thieno[2,3-b]pyridin-6-one 
• 724746-07-0 6-methyl-5-phenyl-2-(pyridin-2-yl)thieno[2,3-d]pyrimidin-4(3H)-one 
• 724746-10-5 6-methyl-5-phenyl-2-(pyridin-3-yl)thieno[2,3-d]pyrimidin-4(3H)-one 
• 724746-13-8 6-methyl-5-phenyl-2-(pyridin-4-yl)thieno[2,3-d]pyrimidin-4(3H)-one 
• 379238-96-7 C₁₃H₁₀N₂S₂ 
• 1175819-21-2 C₁₇H₁₆N₂O₂S₂ 
• 1018578-66-9 [(6-methyl-5-phenylthieno[2,3-d]pyrimidin-4-yl)thio]acetic acid 
• 325806-59-5 C₁₈H₁₇NO₅S 
• 128118-40-1 2-(3-Carboxy-propionylamino)-5-methyl-4-phenyl-thiophene-3-carboxylic acid 

Relevant academic research and scientific papers

Identification of 4-methoxythieno[2,3-d]pyrimidines as FGFR1 inhibitors

Aim. To identify novel FGFR1 inhibitors using virtual screening approach. Methods. We used methods of organic synthesis, molecular docking via the Autodock 4.2.6 program package and in vitro biochemical tests with γ-32P. Results. In vitro experiments showed that 9 of 23 tested compounds possess inhibitory activity against FGFR1 with IC50 values in the range from 0.9 to 5.6 μM. Conclusions. Nine FGFR1 inhibitors were developed. The mode of compounds binding with the ATP-acceptor site was determined using molecular docking methods and the dependence of the compounds’ activity on the substituents R1, R4 and R5 was evaluated.

Design and synthesis of novel protein kinase CK2 inhibitors on the base of 4-aminothieno[2,3-d]pyrimidines

An extension of our previous research work has resulted in a number of new ATP-competitive CK2 inhibitors that have been identified among 4-aminothieno[2,3-d]pyrimidine derivatives. The most active compounds obtained in the course of the research are 3-(5-p-tolyl-thieno[2,3-d]pyrimidin-4-ylamino)-benzoic acid, 5e (NHTP23, IC50 = 0.01 μM), 3-(5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino)-benzoic acid, 5g (NHTP25, IC50 = 0.065 μM) and 3-(6-methyl-5-phenyl-thieno[2,3-d]pyrimidin-4-ylamino)-benzoic acid, 5n (NHTP33, IC50 = 0.008 μM). Structure-activity relationships of the tested 4-aminothieno[2,3-d]pyrimidine derivatives have been studied and their binding mode with ATP-acceptor site of CK2 has been proposed. A negative effect of intramolecular hydrogen bonding in the compounds' structure is discussed.

Mg/La mixed oxide as an efficient heterogeneous basic catalyst for synthesis of 2-aminothiophenes under microwave irradiation

Microwave-assisted synthesis of 2-aminothiophenes via a Gewald reaction using a heterogeneous strong basic Mg/La mixed oxide catalyst is described.

Synthesis and antimicrobial activity of novel 2-(pyridin-2-yl)thieno[2,3-d] pyrimidin-4 (3H)-ones

In the present study, some new 2-(pyridin-2-yl)thieno[2,3-d]pyrimidin-4(3H) -ones derivatives (IIa-o) were synthesized. The target compounds (IIa-o) were synthesized through the acid catalyzed condensation of 2-cyano, 3-cyano, and 4-cyano-pyridines with various 2-amino-3-carbethoxythiophenes (Ia-e). All thiophene derivatives were synthesized by Gewald reaction. The structures of the newly synthesized compounds were confirmed by UV-Visible, FT-IR, 1H-NMR, and mass spectral studies. All synthesized compounds were evaluated for their antimicrobial activity against various gram-positive and gram-negative bacterial and fungal strains. Amongst the synthesized compounds IIa, IIb, IId, IIe, and IIm were found to be active. TUeBITAK.

THIENOPYRIDONE DERIVATIVES AS AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS

The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonists. The invention is also directed to intermediates and to a method of preparation of compounds of formula (I).

Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin- 4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2

A novel series of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids has been synthesized and tested in vitro towards human protein kinase CK2. It was revealed that the most active compounds inhibiting CK2 are 3-{[5-(4-methylphenyl)thieno[2,3-d]pyrimidin-4-yl]thio}propanoic acid and 3-{[5-(4-ethoxyphenyl)thieno[2,3-d]pyrimidin-4-yl]thio}propanoic acid (IC 50 values are 0.1 μM and 0.125 μM, respectively). Structure-activity relationships of 28 tested thienopyrimidine derivatives have been studied and binding mode of this chemical class has been predicted. Evaluation of the inhibitors on seven protein kinases revealed considerable selectivity towards CK2.

THIENOPYRIDONE DERIVATIVES AS AMP-ACTIVATED PROTEIN KINASE (AMPK) ACTIVATORS

The present invention relates to compounds of formula (I) wherein R1, R2 and R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diseases and disorders modulated by AMP agonis

Efficient synthesis of substituted 2-amino-3-carbethoxythiophenes

A microwave-assisted method for the synthesis of a variety of thiophene o-aminoesters (2a-l) has been developed, starting from an appropriate aldehyde, methyl ketone or acetoacetate ester with ethyl cyanoacetate in the presence of elemental sulfur. Copyright Taylor & Francis Group, LLC.